Caplin Point Laboratories
- Market cap
- ₹ 16,898 Cr.
- P/E
- 26.9x
- P/B
- 4.77x
- 52-week range
- 1,500.3 – 2,990
- ROE
- 21%
- ROCE
- 25%
- Dividend yield
- 0.4%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Caplin Point Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)26.9 against a typical 34: cheaper than most peers (1st = cheapest).88th of 220
- Sales growth+19.6% against a typical +15.6% from a year earlier.82nd of 197
- Profit growth+18.5% against a typical +18.9% from a year earlier.81st of 160
- Share price, 3 months−10% against a typical −0.5%.144th of 200
- Size₹ 16,898 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).27th of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 12 Aug 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended June 30, 2026 and to recommend final dividend |
| 14 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and declaration of dividend, if any. |
| 5 Feb 2026 | Financial Results | To consider and approve the unaudited financial results for the period ended December 31, 2025 |
| 5 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 7 Aug 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2025 and dividend |
| 15 May 2025 | Financial Results/Dividend | To consider and approve the annual audited financial results of the company for the period ended March 31, 2025 and declaration of interim dividend. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 410 | 436 | 453 | 459 | 483 | 493 | 502 | 510 | 534 | 543 | 600 | 610 |
| Expenses | 273 | 293 | 308 | 307 | 318 | 331 | 334 | 332 | 345 | 353 | 396 | 397 |
| Operating Profit | 137 | 142 | 145 | 152 | 165 | 162 | 168 | 178 | 189 | 190 | 204 | 213 |
| OPM % | 34% | 33% | 32% | 33% | 34% | 33% | 33% | 35% | 35% | 35% | 34% | 35% |
| Other Income | 21 | 17 | 17 | 19 | 21 | 31 | 26 | 23 | 30 | 34 | 28 | 34 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 12 | 14 | 16 | 16 | 17 | 16 | 17 | 16 | 18 | 19 | 19 | 22 |
| Profit before tax | 146 | 145 | 146 | 154 | 168 | 177 | 177 | 184 | 201 | 204 | 213 | 225 |
| Tax % | 20% | 18% | 17% | 19% | 22% | 21% | 18% | 18% | 20% | 19% | 19% | 20% |
| Net Profit | 116 | 120 | 121 | 125 | 131 | 140 | 145 | 151 | 160 | 166 | 173 | 179 |
| EPS in Rs | 15.13 | 15.43 | 16.01 | 16.31 | 17.21 | 18.28 | 18.76 | 20.1 | 20.32 | 21.56 | 22.38 | 23.27 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 25%
- 5 Years
- 16%
- 3 Years
- 14%
- TTM
- 15%
- 10 Years
- 30%
- 5 Years
- 22%
- 3 Years
- 20%
- TTM
- 18%
- 10 Years
- 27%
- 5 Years
- 27%
- 3 Years
- 36%
- TTM
- —
- 10 Years
- 25%
- 5 Years
- 23%
- 3 Years
- 22%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Caplin Point Laboratories | ₹ 2,351.00 | ₹ 16,898 Cr. | 26.9x | 4.8x | 21% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- D. Muralidharan
- Chief Financial Officer
- G. Venkatram
- Compliance Officer, General Counsel, Company Secretary
- Sridhar Ganesan
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.